These data indicated that SCE selectively decreased Smad3 expression and then inhibited TGF-β/Smad3 signaling activation, which ameliorated fibrotic responses in CFs. The gene discussed is TGFB1; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.